Sernova Biotherapeutics Inc SEOVF
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -5.64% | -2.25% | -22.12% | -20.57% | -17.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.45% | -44.97% | -54.84% | -49.66% | -51.24% |
| Operating Income | 40.45% | 44.97% | 54.84% | 49.66% | 51.24% |
| Income Before Tax | 37.49% | 10.53% | 56.65% | 55.33% | 46.41% |
| Income Tax Expenses | -309.09% | -- | -1,253.33% | -876.47% | -- |
| Earnings from Continuing Operations | 38.90% | 11.40% | 57.99% | 56.48% | 46.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.90% | 11.40% | 57.99% | 56.48% | 46.13% |
| EBIT | 40.45% | 44.97% | 54.84% | 49.66% | 51.24% |
| EBITDA | 37.26% | 44.46% | 54.49% | 50.42% | 52.75% |
| EPS Basic | 46.67% | 17.28% | 59.02% | 58.26% | 50.28% |
| Normalized Basic EPS | 45.61% | 16.00% | 57.89% | 56.94% | 49.56% |
| EPS Diluted | 46.67% | 17.28% | 59.02% | 58.26% | 50.28% |
| Normalized Diluted EPS | 45.61% | 16.00% | 57.89% | 56.94% | 49.56% |
| Average Basic Shares Outstanding | 14.96% | 6.89% | 2.72% | 3.54% | 8.20% |
| Average Diluted Shares Outstanding | 14.96% | 6.89% | 2.72% | 3.54% | 8.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |